rucaparib,abiraterone,enzalutamide,docetaxel
pfizer,astellas,clovis oncology
['rucaparib', 'brca', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'docetaxel']
rucaparib does not demonstrate a statistically significant os advantage in patients with mcrpc and brca or altered atm versus docetaxel or second-generation arpi (results are immature) #gu23 
Medical oncologist. Clinical researcher focused in GU tumors. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain